Skip to main content
. 2022 Apr 5;149(3):1195–1209. doi: 10.1007/s00432-022-03938-x

Table 2.

Use of NACT in different subtypes of breast cancer

Characteristic HR + /HER2−
N = 69,522
HR−/HER2−
N = 9731
HR + /HER2 + 
N = 8281
HR−/HER2 + 
N = 3927
No NACT 65,461 (94.2%) 6633 (68.2%) 6088 (73.5%) 2674 (68.1%)
NACT 4061 (5.8%) 3098 (31.8%) 2193 (26.5%) 1253 (31.9%)

NACT neoadjuvant chemotherapy